AUSTIN, Texas–(BUSINESS WIRE)–Wenzel Spine, Inc., a medical device company focused on providing minimally invasive, stand-alone alternatives to traditional spinal fusion, announced today the publication of a new peer-reviewed paper providing a system overview and detailing clinical results of over 700 patients treated using the stand-alone, expandable, VariLift Interbody Fusion System.
The recently released paper, published in Medical Devices: Research and Evidence, provides an in-depth analysis of the VariLift Interbody Fusion System’s design rational, functionality, and retrospective clinical results. Clinical results from 713 patients were reported from 3 European and 2 US sites. 682 patients (96%) were treated with stand-alone use of the VariLift System.
Frank Fichtel, M.D., board certified neurosurgeon and participating surgeon in the study, said, “This retrospective study of such a large patient population further demonstrates the long-term effectiveness of stand-alone interbody fusion using the VariLift System and the ability to obtain excellent clinical outcomes across multiple sites and countries.”
As the only expandable interbody fusion device on the market with FDA clearance for stand-alone use, VariLift offers a unique solution for both lumbar and cervical interbody fusion procedures.
Chad Neely, Chief Executive Officer for Wenzel Spine, commented, “This clinical summary further demonstrates the long-term clinical effectiveness of stand-alone interbody fusion using our proprietary expandable IBFD technology. As we look towards the future of progressive spinal surgery techniques, we are confident that VariLift will continue to pioneer true MIS fusion that improves long-term clinical outcomes, shortens hospital stays, and creates more active and rapid recovery periods. We look forward to continued publication of prospective clinical data.”
Wenzel Spine’s Cervical and Lumbar VariLift® Stand-Alone Expandable Interbody Fusion Systems are commercially available in the US and Europe.
